BRAINSTORM CELL THERAPUTC
BCLI
BCLI was delisted on the 17th of July, 2025.
34 hedge funds and large institutions have $264K invested in BRAINSTORM CELL THERAPUTC in 2025 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 5 closing their positions.
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
6% more funds holding
Funds holding: 32 → 34 (+2)
13.96% less ownership
Funds ownership: 17.95% → 3.99% (-14%)
76% less capital invested
Capital invested by funds: $1.09M → $264K (-$827K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCM
Gunderson Capital Management
Mt. Pleasant,
South Carolina
|
+$29K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$13.6K |
| 3 |
TCM
Traynor Capital Management
Malvern,
Pennsylvania
|
+$12.3K |
| 4 |
LPL Financial
San Diego,
California
|
+$12K |
| 5 |
AIP
Almanack Investment Partners
Wayne,
Pennsylvania
|
+$11.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$870K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$20.4K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$4.01K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$254 |
| 5 |
JP Morgan Chase
New York
|
-$215 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DJSG
26
D.J. St. Germain
Springfield,
Massachusetts
| $37 | – | – | – |
|
27
BNP Paribas Financial Markets
Paris,
France
| $27 | – | – | – |
|
|
CIAS
28
CBIZ Investment Advisory Services
Independence,
Ohio
| $15 | – | – | – |
|
|
WIM
29
Westside Investment Management
Santa Monica,
California
| $14 | – | – | – |
|
30
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| $11 | – | – | – |
|
|
CA
31
CoreCap Advisors
Southfield,
Michigan
| $9 | – | – | – |
|
|
32
Fidelity Investments
Boston,
Massachusetts
| $7 | -$254 | -227 | -97% |
|
|
BWL
33
Bogart Wealth LLC
Mclean,
Virginia
| $2 | – | – | – |
|
|
AC
34
Armistice Capital
New York
| – | -$870K | -690,666 | Closed |
|
|
TSS
35
Two Sigma Securities
New York
| – | -$20.4K | -16,153 | Closed |
|
|
36
JP Morgan Chase
New York
| – | -$215 | -171 | Closed |
|
|
TRCT
37
Tower Research Capital (TRC)
New York
| – | -$170 | -135 | Closed |
|
|
CWM
38
Centricity Wealth Management
Westerville,
Ohio
| – | -$25 | -20 | Closed |
|
BCLI Hedge Fund Activity: Q2 2025 in Review
34 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in BRAINSTORM CELL THERAPUTC (BCLI) for Q2 2025, worth a combined $264K — down 76% from $1.09M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BCLI positions and 5 closed out — a net gain of 2 holders — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Gunderson Capital Management, opening a new position worth an estimated $29K. The largest seller was Armistice Capital, exiting entirely with an estimated $870K sold.
- 34 institutional investors held BRAINSTORM CELL THERAPUTC (BCLI) as of Q2 2025, up from 32 in Q1 2025.
- Funds reported $264K of BRAINSTORM CELL THERAPUTC stock for Q2 2025, down 76% quarter-over-quarter.
- 7 funds opened new BRAINSTORM CELL THERAPUTC positions in Q2 2025 and 5 closed out, a net change of +2 holders.
- The largest BRAINSTORM CELL THERAPUTC buyer in Q2 2025 was Gunderson Capital Management, an estimated $29K added.
- The largest BRAINSTORM CELL THERAPUTC seller in Q2 2025 was Armistice Capital, an estimated $870K sold.
Based on aggregated 13F filings for Q2 2025.